Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole cell engineering reconstructing complex molecules in yeast to bring to market next generation plant inspired medicines. Antheia’s team of scientists and technologists is headquartered in Menlo Park, California. For more information, visit www.antheia.bio.
Location: United States, California, Menlo Park
Employees: 11-50
Total raised: $146M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Western Te... | westerntec... |
| - | Irregular ... | irregular.... |
| - | Lam Resear... | lamcapital... |
| - | Civilizati... | civilizati... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.06.2025 | Series C | $56M | - |
| 25.07.2024 | - | $17M | - |
| 03.07.2021 | Series B | $73M | - |
Mentions in press and media 27
| Date | Title | Description |
| 02.02.2026 | Antheia Secures $24M, Bolstering U.S. Drug Manufacturing Resilience | Antheia, a biosynthesis leader, closed its Series C financing with an additional $24 million, bringing its year-long capital securement past $175 million. This vital funding drives the expansion of U.S. pharmaceutical manufacturing capacity... |
| 27.01.2026 | Antheia Raises $24M in Second Close of Series C Financing | Antheia, a Menlo Park, CA-based biosynthesis company delivering pharmaceutical manufacturing, completed a second close of its Series C financing, raising an additional $24M. The round was led by ATHOS KG and America’s Frontier Fund, with pa... |
| 07.07.2025 | Family offices ramp up deal-making in June with bets on biotech | After a slow spring, investment firms of the ultra-rich made 60 direct investments in June, according to Fintrx. Family offices flocked to biotech and health-care firms such as Antheia, seeking to make an impact and returns at the same time... |
| 08.06.2025 | Antheia's $56 Million Boost: A Game Changer in Pharmaceutical Manufacturing | Antheia, a Menlo Park-based pharmaceutical ingredient manufacturer, has struck gold with its recent $56 million Series C funding round. This infusion of capital, led by the Global Health Investment Corporation (GHIC), marks a significant le... |
| 07.06.2025 | Antheia: $56 Million Series C Raised For Advancing Global Commercialization Strategy | Antheia, a pharmaceutical ingredient manufacturer transforming essential medicine supply chains, announced it has raised $56 million in Series C financing. The Series C funding round was led by Global Health Investment Corporation (GHIC), a... |
| 03.06.2025 | Antheia Raises $56M in Series C Funding | Antheia, a Menlo Park, CA-based pharmaceutical ingredient manufacturer, raised $56M in Series C funding. The round wads led by Global Health Investment Corporation. Additional new investors included ATHOS KG and Federov, while existing inve... |
| 25.07.2024 | Antheia: Pharmaceutical Ingredient Producer Secures $17 Million In New Funding | Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, announced $17 million in new funding through a government project agreement through the Biopharmaceutical Manufacturing Preparedness Consorti... |
| 21.07.2024 | Antheia Raises $17M in Funding | Antheia, a Menlo Park, CA-based pharmaceutical ingredient manufacturer, raised $17M in funding. The funding included a non-dilutive two-year project agreement up to $11M through the BioMaP Consortium and additional investment from In-Q-Tel,... |
| 14.03.2024 | Antheia und Olon führen Zusammenarbeit bei der Herstellung von KSMs und APIs für unentbehrliche Medikamente aus Antheias Produktpipeline fort | Olon unterstützt Antheia bei Scale-up und Kommerzialisierung der ersten Produkte MENLO PARK, Kalif., und MAILAND, Italien, March 14, 2024 (GLOBE NEWSWIRE) -- Der pharmazeutische Wirkstoffhersteller Antheia, der Supply Chains für essenzielle... |
| 14.03.2024 | Antheia et Olon poursuivent leur partenariat pour la biofabrication de matières premières essentielles et de principes actifs pharmaceutiques d'Antheia pour les médicaments essentiels | Olon soutiendra la poursuite de la mise à l'échelle et de la commercialisation des produits de première génération d'Antheia MENLO PARK, Californie et MILAN, Italie, 14 mars 2024 (GLOBE NEWSWIRE) -- Antheia, le fabricant d'ingrédients pharm... |
Show more